Skip to main content
. 2021 Mar 27;22(7):3474. doi: 10.3390/ijms22073474

Table 1.

Different clinicopathological characteristics between BRAF V600E- and V600K-mutant melanoma patients.

Mutation Frequency (among BRAF V600 Mutations) DFS PFS (with TT) TMB Response to ICIs
V600E 70–88% Longer Longer Lower Good
V600K 10–20% Shorter Shorter Higher Better

DFS: disease-free survival; PFS: progression-free survival; TT: targeted therapy; TMB: tumour mutational burden; ICIs: immune checkpoint inhibitors.